| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income | 811,276 | 536,666 | 242,677 | 671,718 |
| Depreciation and amortization | 106,462 | 69,835 | 34,063 | 96,230 |
| Impairment charge | 0 | 0 | 0 | 250 |
| Provision for credit losses | 5,979 | 4,360 | 2,890 | 5,080 |
| Deferred income taxes | 99,675 | 6,427 | 3,948 | -28,870 |
| Share-based compensation expense | 43,902 | 29,469 | 14,615 | 46,037 |
| Other | 3,244 | 1,491 | 456 | 1,034 |
| Accounts receivable | 82,586 | 74,889 | 45,240 | 56,087 |
| Inventories | 2,202 | 4,081 | -2,163 | 24,756 |
| Other assets and liabilities | 160,944 | 139,906 | 10,325 | 45,272 |
| Accounts payable | -4,977 | -12,113 | -8,123 | 2,347 |
| Deferred revenue | 6,216 | 6,446 | 838 | -735 |
| Net cash provided by operating activities | 826,045 | 423,705 | 237,962 | 666,976 |
| Purchases of property and equipment | 95,242 | 64,128 | 30,026 | 91,667 |
| Acquisition of intangible assets | 13,350 | - | - | - |
| Equity investments | 756 | - | - | - |
| Acquisition of a business | 0 | 0 | 0 | 76,694 |
| Proceeds from net investment hedges | 1,239 | 890 | 416 | 1,142 |
| Net cash used by investing activities | -108,109 | -63,238 | -29,610 | -167,219 |
| Borrowings under credit facility, net | 205,000 | 329,000 | 69,500 | 0 |
| Payments of senior notes | 103,386 | 103,386 | - | 75,000 |
| Payments of acquisition-related contingent consideration and holdbacks | - | - | - | 0 |
| Repurchases of common stock | 979,190 | 738,995 | 400,890 | 591,042 |
| Proceeds from exercises of stock options and employee stock purchase plans | 75,493 | 24,523 | 7,193 | 31,237 |
| Shares withheld for statutory tax withholding payments on restricted stock | 7,179 | 7,094 | 6,124 | 10,486 |
| Net cash used by financing activities | -809,262 | -495,952 | -330,321 | -645,291 |
| Net effect of changes in exchange rates on cash | 11,226 | 11,813 | -2,327 | 238 |
| Net decrease in cash and cash equivalents | -80,100 | -123,672 | -124,296 | -145,296 |
| Cash and cash equivalents at beginning of period | 288,266 | 288,266 | 288,266 | 453,932 |
| Cash and cash equivalents at end of period | 208,166 | 164,594 | 163,970 | 308,636 |
IDEXX LABORATORIES INC DE (IDXX)
IDEXX LABORATORIES INC DE (IDXX)